Pyrotinib Maleate single box market price analysis

Pyrotinib Maleate (Pyrotinib Maleate) is an oral small molecule tyrosine kinase inhibitor independently developed in China, with the trade name Irene. It is mainly used in patients with HER2-positive advanced or metastatic breast cancer, especially those whose disease has progressed after receiving standard treatments such as trastuzumab. By irreversibly inhibiting HER2 and part of the EGFR signaling pathway, pyrotinib effectively inhibits tumor cell proliferation and metastasis, while delaying disease progression and improving patients' overall quality of life. In domestic clinical practice, pyrotinib is often used in combination with chemotherapy drugs to improve efficacy and reduce the limitations of monotherapy.

In terms of drug accessibility, pyrotinib has been independently developed and marketed in China and has been included in the medical insurance directory, which means that patients can enjoy a certain proportion of reimbursement when using it, reducing the financial burden. The market price of a single box is about 2,000 to 4,000 yuan, and the price fluctuates due to differences in regions, medical insurance policies and hospital procurement. Compared with overseas imported drugs, its price is more accessible, which helps improve treatment coverage and compliance for domestic HER2-positive breast cancer patients. It is worth noting that there are currently no generic drugs of pyrotinib on the market in China, so the original drug is still the only available clinical option.

In addition, the clinical application of pyrotinib is not limited to local control of breast cancer, but also shows potential value in patients with brain metastases. Due to its molecular structure and oral accessibility, it is more convenient for patients in long-term management and does not require frequent hospitalization or intravenous infusions. Clinicians can develop an individualized plan based on the patient's condition, adjust the dose or combine it with chemotherapy to optimize the efficacy. In the future, with the accumulation of more clinical research data and the exploration of new indications, pyrotinib is expected to expand its application scope inHER2-related tumors, while further improving patients' quality of life and survival expectations.

Reference materials:https://www.drugs.com